Artera
UnknownAI-powered multimodal platform for personalized precision oncology and cancer risk stratification
Informations sur l’outil
Qu'est-ce que Artera ?
Artera is a multimodal artificial intelligence platform that analyzes digital pathology images and clinical data to deliver personalized risk estimates, prognostic insights, and therapeutic guidance for cancer management, with validated tests focused on prostate and breast cancer.
Fonctionnalités principales
Multimodal AI (MMAI) Platform
Analyzes digital pathology and clinical data for personalized cancer management and has been validated in dozens of large, randomized phase III clinical trials.
FDA De Novo Authorization for ArteraAI Prostate
First-of-its-kind AI-powered digital pathology risk stratification tool with De Novo Authorization from the FDA, regulated as Software as a Medical Device (SaMD), following earlier Breakthrough Device Designation.
ArteraAI Prostate Test
Offers therapeutic insights in early-stage prostate cancer, predicts which NCCN Intermediate-risk patients will benefit from short-term androgen deprivation therapy with radiation, and is the first and only AI test included in the NCCN Guidelines for Prostate Cancer as a prognostic test. Also available for post-RP, biopsy, and metastatic hormone-sensitive prostate cancer (mHSPC).
Non-tissue-consuming digital pathology analysis
Uses image data from existing H&E slides with no additional staining or preparation required and does not consume tissue.
Rapid turnaround results
Results can be shared within 1-2 days after receipt of the patient’s specimen by the CLIA lab.
Diverse population performance
Demonstrates consistent prognostic performance between African American and non-African American men.
ArteraAI Breast Cancer Test
Provides actionable AI-powered insights for breast cancer as part of the multimodal platform offering tests across multiple cancers.
Expansion to metastatic hormone-sensitive prostate cancer (mHSPC)
First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC.
Cas d'utilisation
- #1
Prostate cancer risk stratification and treatment personalization
Guides clinicians and patients with prognostic and therapeutic insights for early-stage, intermediate-risk, post-prostatectomy, salvage radiation, and metastatic hormone-sensitive prostate cancer to inform decisions such as use of androgen deprivation therapy or treatment intensification.
- #2
Breast cancer prognostic insights
Delivers personalized AI-based insights to support breast cancer care and management.
- #3
Ordering tests for clinical decision support
Enables clinicians to order ArteraAI Prostate or Breast Cancer Tests via an ordering portal and provides patients with information on available tests.
Plans tarifaires
Test is covered by insurance; a Billing page is listed. No specific pricing tiers, costs, or payment models are detailed on the source page.
Alternatives
Foire aux questions
What is Artera?
Has ArteraAI Prostate received FDA authorization?
Does the ArteraAI Prostate Test consume tissue samples?
How long does it take to receive results?
Is the ArteraAI Prostate Test included in clinical guidelines?
What is known about pricing and insurance coverage?
Artera Contacts et réseaux sociaux
- Assistance
- Site Internet :
- Twitter
- LinkedIn
Avis
Partagez votre expérience avec cet outil...